Sept. 18: Researchers found using a different drug to treat HER-2-positive breast cancer was significantly more successful at reducing tumor size and keeping the patient alive longer without progression of disease than the current standard of care. The drug, called Enhertu, is already approved for those with metastatic cancer or as a second-line treatment option for HER2-positive breast cancer that has continued to spread after initial therapy. Read more in this ABC News story HERE.
Sept. 24: A computer program trained to see patterns among thousands of breast ultrasound images can aid physicians in accurately diagnosing breast cancer, a new study shows. Read the full story in MedicalXpress HERE.
Sept. 27: The negative effects to the heart due to the chemotherapy drug doxorubicin could be prevented or reduced in patients with the mutation by treating them with retinoic acid, according to a new study. Clinical trials on this new treatment will likely begin soon. Read the full story in MedicalXpress HERE.
Sept. 29: A new report indicates that MRIs are cost effective for detecting breast cancer for women with very dense breasts detected by mammography. This is important for women with dense breasts because they have increased risk of developing breast cancer, and because mammography tends to be inaccurate in detecting breast cancer for them. Read more in News Medical HERE.